Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INOVIO PHARMACEUTICALS, INC.INO · Entity 6589 | Chief Scientific Officer | May 20, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INOVIO PHARMACEUTICALS, INC.
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,823 |
Ending reported balance
After 2026-05-20 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-20 · Exercise / conversion · Acquired 6,027 · Balance 48,986 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 18,081 restricted stock units was as follows: 6,027 shares vested on May 20, 2026; 6,027 shares will vest on May 20, 2027; 6,027 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Row 2 · 2026-05-20 · Tax withholding · Disposed 2,163 · Balance 46,823 F2: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 12,054 |
Reported balance
After 2026-05-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-20 · Exercise / conversion · Disposed 6,027 · Balance 12,054 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 18,081 restricted stock units was as follows: 6,027 shares vested on May 20, 2026; 6,027 shares will vest on May 20, 2027; 6,027 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 27,440 |
Reported balance
After 2026-05-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-20 · Grant · Acquired 27,440 · Balance 27,440 F5: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the restricted stock units granted on May 20, 2026 was as follows: 9,147 shares will vest on February 26, 2027; 9,147 shares will vest on February 26, 2028; and 9,146 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F6: The restricted stock units were approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the restricted stock units were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026. |
| Common Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.73 · Expires 2036-05-20 | Direct | 34,160 |
Reported balance
After 2026-05-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-20 · Grant · Acquired 34,160 · Balance 34,160 F3: The stock option grant was approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the stock options were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026. F4: The vesting schedule for the options granted on May 20, 2026 was as follows: 11,387 shares will vest on February 26, 2027; 11,387 shares will vest on February 26, 2028; 11,386 shares will vest on February 26, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 18,081 restricted stock units was as follows: 6,027 shares vested on May 20, 2026; 6,027 shares will vest on May 20, 2027; 6,027 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
F2: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein.
F3: The stock option grant was approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the stock options were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026.
F4: The vesting schedule for the options granted on May 20, 2026 was as follows: 11,387 shares will vest on February 26, 2027; 11,387 shares will vest on February 26, 2028; 11,386 shares will vest on February 26, 2029.
F5: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the restricted stock units granted on May 20, 2026 was as follows: 9,147 shares will vest on February 26, 2027; 9,147 shares will vest on February 26, 2028; and 9,146 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
F6: The restricted stock units were approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the restricted stock units were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2026 Filed May 21, 2026 20:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 27,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001770390-26-000005 · wk-form4_1779393944.xml · derivative · entry 5 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,440 Underlying: Common Stock · 27,440 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the restricted stock units granted on May 20, 2026 was as follows: 9,147 shares will vest on February 26, 2027; 9,147 shares will vest on February 26, 2028; and 9,146 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F6 · date: The restricted stock units were approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the restricted stock units were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026. F5 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the restricted stock units granted on May 20, 2026 was as follows: 9,147 shares will vest on February 26, 2027; 9,147 shares will vest on February 26, 2028; and 9,146 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F5 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the restricted stock units granted on May 20, 2026 was as follows: 9,147 shares will vest on February 26, 2027; 9,147 shares will vest on February 26, 2028; and 9,146 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 20, 2026 Filed May 21, 2026 20:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 34,160 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001770390-26-000005 · wk-form4_1779393944.xml · derivative · entry 4 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,160 Underlying: Common Stock · 34,160 shares Expires 2036-05-20 F3 · date: The stock option grant was approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the stock options were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026. F4 · derivative.exercise_date: The vesting schedule for the options granted on May 20, 2026 was as follows: 11,387 shares will vest on February 26, 2027; 11,387 shares will vest on February 26, 2028; 11,386 shares will vest on February 26, 2029. Read SEC document |
| May 20, 2026 Filed May 21, 2026 20:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 6,027 | $0.00 | $0.00 |
DisclosureSEC source: 0001770390-26-000005 · wk-form4_1779393944.xml · derivative · entry 3 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,054 Underlying: Common Stock · 6,027 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 18,081 restricted stock units was as follows: 6,027 shares vested on May 20, 2026; 6,027 shares will vest on May 20, 2027; 6,027 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 18,081 restricted stock units was as follows: 6,027 shares vested on May 20, 2026; 6,027 shares will vest on May 20, 2027; 6,027 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 18,081 restricted stock units was as follows: 6,027 shares vested on May 20, 2026; 6,027 shares will vest on May 20, 2027; 6,027 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 20, 2026 Filed May 21, 2026 20:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 2,163 | $1.23 | $2,660.49 |
DisclosureSEC source: 0001770390-26-000005 · wk-form4_1779393944.xml · nonDerivative · entry 2 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,823 F2 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. Read SEC document |
| May 20, 2026 Filed May 21, 2026 20:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 6,027 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001770390-26-000005 · wk-form4_1779393944.xml · nonDerivative · entry 1 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,986 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 18,081 restricted stock units was as follows: 6,027 shares vested on May 20, 2026; 6,027 shares will vest on May 20, 2027; 6,027 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 4,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001770390-26-000004 · wk-form4_1779134799.xml · derivative · entry 3 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,771 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 14,313 restricted stock units was as follows: 4,771 shares vested on May 15, 2024; 4,771 shares vested on May 15, 2025; and 4,771 shares vested on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 14,313 restricted stock units was as follows: 4,771 shares vested on May 15, 2024; 4,771 shares vested on May 15, 2025; and 4,771 shares vested on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 14,313 restricted stock units was as follows: 4,771 shares vested on May 15, 2024; 4,771 shares vested on May 15, 2025; and 4,771 shares vested on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 1,712 | $1.30 | $2,225.60 |
DisclosureSEC source: 0001770390-26-000004 · wk-form4_1779134799.xml · nonDerivative · entry 2 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,959 F2 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 4,771 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001770390-26-000004 · wk-form4_1779134799.xml · nonDerivative · entry 1 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 14,313 restricted stock units was as follows: 4,771 shares vested on May 15, 2024; 4,771 shares vested on May 15, 2025; and 4,771 shares vested on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:55 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 21,560 | $0.00 | $0.00 |
DisclosureSEC source: 0001770390-26-000003 · wk-form4_1772747737.xml · derivative · entry 2 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,560 Underlying: Common Stock · 21,560 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 21,560 restricted stock units granted on March 4, 2026 was as follows: 7,187 shares will vest on February 26, 2027; 7,187 shares will vest on February 26, 2028; and 7,186 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 21,560 restricted stock units granted on March 4, 2026 was as follows: 7,187 shares will vest on February 26, 2027; 7,187 shares will vest on February 26, 2028; and 7,186 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 21,560 restricted stock units granted on March 4, 2026 was as follows: 7,187 shares will vest on February 26, 2027; 7,187 shares will vest on February 26, 2028; and 7,186 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:55 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 26,840 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001770390-26-000003 · wk-form4_1772747737.xml · derivative · entry 1 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,840 Underlying: Common Stock · 26,840 shares Expires 2036-02-26 F1 · derivative.exercise_date: The vesting schedule for the 26,840 options granted on March 4, 2026 was as follows: 8,947 shares will vest on February 26, 2027; 8,947 shares will vest on February 26, 2028; 8,946 shares will vest on February 26, 2029. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:49 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 7,366 | $0.00 | $0.00 |
DisclosureSEC source: 0001770390-26-000002 · wk-form4_1772228940.xml · derivative · entry 6 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,732 Underlying: Common Stock · 7,366 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 22,098 restricted stock units granted on February 27, 2025 was as follows: 7,366 shares vested on February 26, 2026; 7,366 shares will vest on February 26, 2027; 7,366 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 22,098 restricted stock units granted on February 27, 2025 was as follows: 7,366 shares vested on February 26, 2026; 7,366 shares will vest on February 26, 2027; 7,366 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 22,098 restricted stock units granted on February 27, 2025 was as follows: 7,366 shares vested on February 26, 2026; 7,366 shares will vest on February 26, 2027; 7,366 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:49 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 5,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001770390-26-000002 · wk-form4_1772228940.xml · derivative · entry 5 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,009 Underlying: Common Stock · 5,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units granted on February 28, 2024 was as follows: 5,010 shares vested on February 26, 2025; 5,010 shares vested on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units granted on February 28, 2024 was as follows: 5,010 shares vested on February 26, 2025; 5,010 shares vested on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units granted on February 28, 2024 was as follows: 5,010 shares vested on February 26, 2025; 5,010 shares vested on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:49 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 3,034 | $1.79 | $5,430.86 |
DisclosureSEC source: 0001770390-26-000002 · wk-form4_1772228940.xml · nonDerivative · entry 4 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,900 F4 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (3) herein. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:49 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 7,366 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001770390-26-000002 · wk-form4_1772228940.xml · nonDerivative · entry 3 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 22,098 restricted stock units granted on February 27, 2025 was as follows: 7,366 shares vested on February 26, 2026; 7,366 shares will vest on February 26, 2027; 7,366 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:49 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 2,064 | $1.79 | $3,694.56 |
DisclosureSEC source: 0001770390-26-000002 · wk-form4_1772228940.xml · nonDerivative · entry 2 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,568 F2 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:49 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 5,010 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001770390-26-000002 · wk-form4_1772228940.xml · nonDerivative · entry 1 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units granted on February 28, 2024 was as follows: 5,010 shares vested on February 26, 2025; 5,010 shares vested on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 20, 2025 Filed May 21, 2025 20:58 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 22,419 | $0.00 Strike: $2.13 | $0.00 |
DisclosureSEC source: 0001055726-25-000041 · wk-form4_1747861122.xml · derivative · entry 2 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,419 Underlying: Common Stock · 22,419 shares Expires 2035-05-20 F2 · derivative.exercise_date: The vesting schedule for the 22,419 options is as follows: 11,210 shares will vest on May 20, 2027 and 11,209 shares will vest on May 20, 2028. Read SEC document |
| May 20, 2025 Filed May 21, 2025 20:58 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 18,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-25-000041 · wk-form4_1747861122.xml · derivative · entry 1 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,081 Underlying: Common Stock · 18,081 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 18,081 restricted stock units is as follows: 6,027 shares will vest on May 20, 2026; 6,027 shares will vest on May 20, 2027; 6,027 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 18,081 restricted stock units is as follows: 6,027 shares will vest on May 20, 2026; 6,027 shares will vest on May 20, 2027; 6,027 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 18,081 restricted stock units is as follows: 6,027 shares will vest on May 20, 2026; 6,027 shares will vest on May 20, 2027; 6,027 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 15, 2025 Filed May 16, 2025 20:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 4,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-25-000028 · wk-form4_1747426085.xml · derivative · entry 3 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,771 Underlying: Common Stock · 4,771 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 14,313 restricted stock units is as follows: 4,771 shares vested on May 15, 2024; 4,771 shares vested on May 15, 2025; and 4,771 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 14,313 restricted stock units is as follows: 4,771 shares vested on May 15, 2024; 4,771 shares vested on May 15, 2025; and 4,771 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 14,313 restricted stock units is as follows: 4,771 shares vested on May 15, 2024; 4,771 shares vested on May 15, 2025; and 4,771 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 15, 2025 Filed May 16, 2025 20:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 1,708 | $1.95 | $3,330.60 |
DisclosureSEC source: 0001055726-25-000028 · wk-form4_1747426085.xml · nonDerivative · entry 2 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,622 F2 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. Read SEC document |
| May 15, 2025 Filed May 16, 2025 20:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 4,771 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-25-000028 · wk-form4_1747426085.xml · nonDerivative · entry 1 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 14,313 restricted stock units is as follows: 4,771 shares vested on May 15, 2024; 4,771 shares vested on May 15, 2025; and 4,771 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 23:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 22,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-25-000005 · wk-form4_1740783954.xml · derivative · entry 8 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,098 Underlying: Common Stock · 22,098 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 22,098 restricted stock units granted on February 27, 2025 is as follows: 7,366 shares will vest on February 26, 2026; 7,366 shares will vest on February 26, 2027; and 7,366 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F6 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 22,098 restricted stock units granted on February 27, 2025 is as follows: 7,366 shares will vest on February 26, 2026; 7,366 shares will vest on February 26, 2027; and 7,366 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F6 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 22,098 restricted stock units granted on February 27, 2025 is as follows: 7,366 shares will vest on February 26, 2026; 7,366 shares will vest on February 26, 2027; and 7,366 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 23:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 27,402 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001055726-25-000005 · wk-form4_1740783954.xml · derivative · entry 7 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,402 Underlying: Common Stock · 27,402 shares Expires 2035-02-27 F5 · derivative.exercise_date: The vesting schedule for the 27,402 options is as follows: 13,701 shares vested on February 27, 2025 and 13,701 shares will vest on February 26, 2026. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 23:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 5,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-25-000005 · wk-form4_1740783954.xml · derivative · entry 6 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,019 Underlying: Common Stock · 5,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units granted on February 28, 2024 is as follows: 5,010 shares vested on February 26, 2025; 5,010 shares will vest on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units granted on February 28, 2024 is as follows: 5,010 shares vested on February 26, 2025; 5,010 shares will vest on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units granted on February 28, 2024 is as follows: 5,010 shares vested on February 26, 2025; 5,010 shares will vest on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 23:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 3,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-25-000005 · wk-form4_1740783954.xml · derivative · entry 5 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,855 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 11,566 restricted stock units granted on February 26, 2022 was as follows: 3,855 shares vested on February 26, 2023; 3,856 shares vested on February 26, 2024; and 3,855 shares vested on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 11,566 restricted stock units granted on February 26, 2022 was as follows: 3,855 shares vested on February 26, 2023; 3,856 shares vested on February 26, 2024; and 3,855 shares vested on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 11,566 restricted stock units granted on February 26, 2022 was as follows: 3,855 shares vested on February 26, 2023; 3,856 shares vested on February 26, 2024; and 3,855 shares vested on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 23:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 2,059 | $1.98 | $4,076.82 |
DisclosureSEC source: 0001055726-25-000005 · wk-form4_1740783954.xml · nonDerivative · entry 4 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,559 F4 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (3) herein. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 23:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 5,010 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-25-000005 · wk-form4_1740783954.xml · nonDerivative · entry 3 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units granted on February 28, 2024 is as follows: 5,010 shares vested on February 26, 2025; 5,010 shares will vest on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 23:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 1,584 | $1.98 | $3,136.32 |
DisclosureSEC source: 0001055726-25-000005 · wk-form4_1740783954.xml · nonDerivative · entry 2 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,608 F2 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 23:06 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 3,855 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-25-000005 · wk-form4_1740783954.xml · nonDerivative · entry 1 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 11,566 restricted stock units granted on February 26, 2022 was as follows: 3,855 shares vested on February 26, 2023; 3,856 shares vested on February 26, 2024; and 3,855 shares vested on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 15, 2024 Filed May 16, 2024 21:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 4,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-24-000030 · wk-form4_1715893678.xml · derivative · entry 3 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,542 Underlying: Common Stock · 4,771 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 14,313 restricted stock units is as follows: 4,771 shares vested on May 15, 2024; 4,771 shares will vest on May 15, 2025; and 4,771 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 14,313 restricted stock units is as follows: 4,771 shares vested on May 15, 2024; 4,771 shares will vest on May 15, 2025; and 4,771 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 14,313 restricted stock units is as follows: 4,771 shares vested on May 15, 2024; 4,771 shares will vest on May 15, 2025; and 4,771 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.underlying_shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| May 15, 2024 Filed May 16, 2024 21:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 1,703 | $13.07 | $22,258.21 |
DisclosureSEC source: 0001055726-24-000030 · wk-form4_1715893678.xml · nonDerivative · entry 2 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,337 F3 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. Read SEC document |
| May 15, 2024 Filed May 16, 2024 21:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 4,771 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-24-000030 · wk-form4_1715893678.xml · nonDerivative · entry 1 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 14,313 restricted stock units is as follows: 4,771 shares vested on May 15, 2024; 4,771 shares will vest on May 15, 2025; and 4,771 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 22:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 15,029 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-24-000004 · wk-form4_1709158046.xml · derivative · entry 8 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,029 Underlying: Common Stock · 15,029 shares Expires not disclosed F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units is as follows: 5,010 shares will vest on February 26, 2025; 5,010 shares will vest on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F7 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units is as follows: 5,010 shares will vest on February 26, 2025; 5,010 shares will vest on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F7 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units is as follows: 5,010 shares will vest on February 26, 2025; 5,010 shares will vest on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 22:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 18,750 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001055726-24-000004 · wk-form4_1709158046.xml · derivative · entry 7 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2034-02-28 F6 · derivative.exercise_date: The vesting schedule for the 18,750 options is as follows: 4,688 shares vested on February 28, 2024; 4,688 shares will vest on February 28, 2025; 4,687 shares will vest on February 28, 2026; and 4,687 shares will vest on February 28, 2027. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 3,856 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-24-000004 · wk-form4_1709158046.xml · derivative · entry 6 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,855 Underlying: Common Stock · 3,856 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 11,566 restricted stock units is as follows: 3,855 shares vested on February 26, 2023; 3,856 shares vested on February 26, 2024; and 3,855 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 11,566 restricted stock units is as follows: 3,855 shares vested on February 26, 2023; 3,856 shares vested on February 26, 2024; and 3,855 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 11,566 restricted stock units is as follows: 3,855 shares vested on February 26, 2023; 3,856 shares vested on February 26, 2024; and 3,855 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.underlying_shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 1,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-24-000004 · wk-form4_1709158046.xml · derivative · entry 5 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,878 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 5,635 restricted stock units was as follows: 1,879 shares vested on February 26, 2022; 1,878 shares vested on February 26, 2023; and 1,878 shares vested on February 26, 2024. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. F2 · shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 5,635 restricted stock units was as follows: 1,879 shares vested on February 26, 2022; 1,878 shares vested on February 26, 2023; and 1,878 shares vested on February 26, 2024. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 5,635 restricted stock units was as follows: 1,879 shares vested on February 26, 2022; 1,878 shares vested on February 26, 2023; and 1,878 shares vested on February 26, 2024. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. F2 · derivative.underlying_shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 1,581 | $8.16 | $12,900.96 |
DisclosureSEC source: 0001055726-24-000004 · wk-form4_1709158046.xml · nonDerivative · entry 4 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,269 F5 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (4) herein. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 3,856 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-24-000004 · wk-form4_1709158046.xml · nonDerivative · entry 3 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 11,566 restricted stock units is as follows: 3,855 shares vested on February 26, 2023; 3,856 shares vested on February 26, 2024; and 3,855 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 770 | $8.16 | $6,283.20 |
DisclosureSEC source: 0001055726-24-000004 · wk-form4_1709158046.xml · nonDerivative · entry 2 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,994 F3 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 1,878 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-24-000004 · wk-form4_1709158046.xml · nonDerivative · entry 1 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 5,635 restricted stock units was as follows: 1,879 shares vested on February 26, 2022; 1,878 shares vested on February 26, 2023; and 1,878 shares vested on February 26, 2024. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:11 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 171,756 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-23-000042 · wk-form4_1684354280.xml · derivative · entry 1 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,756 Underlying: Common Stock · 171,756 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 171,756 restricted stock units is as follows: 57,252 shares will vest on May 15, 2024; 57,252 shares will vest on May 15, 2025; and 57,252 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · shares: This grant was made under the 2016 Omnibus Incentive Plan. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 171,756 restricted stock units is as follows: 57,252 shares will vest on May 15, 2024; 57,252 shares will vest on May 15, 2025; and 57,252 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 171,756 restricted stock units is as follows: 57,252 shares will vest on May 15, 2024; 57,252 shares will vest on May 15, 2025; and 57,252 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 11, 2023 Filed Mar 13, 2023 21:09 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 59,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-23-000013 · wf-form4_167874172348787.xml · derivative · entry 3 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 59,737 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. On March 11, 2020, the reporting person was granted 179,211 restricted stock units, vesting as follows: 59,737 shares vested on March 11, 2021; 59,737 shares vested on March 11, 2022; and 59,737 shares vested on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On March 11, 2020, the reporting person was granted 179,211 restricted stock units, vesting as follows: 59,737 shares vested on March 11, 2021; 59,737 shares vested on March 11, 2022; and 59,737 shares vested on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On March 11, 2020, the reporting person was granted 179,211 restricted stock units, vesting as follows: 59,737 shares vested on March 11, 2021; 59,737 shares vested on March 11, 2022; and 59,737 shares vested on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 11, 2023 Filed Mar 13, 2023 21:09 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 20,658 | $1.13 | $23,343.54 |
DisclosureSEC source: 0001055726-23-000013 · wf-form4_167874172348787.xml · nonDerivative · entry 2 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,637 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| March 11, 2023 Filed Mar 13, 2023 21:09 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 59,737 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-23-000013 · wf-form4_167874172348787.xml · nonDerivative · entry 1 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. On March 11, 2020, the reporting person was granted 179,211 restricted stock units, vesting as follows: 59,737 shares vested on March 11, 2021; 59,737 shares vested on March 11, 2022; and 59,737 shares vested on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 22:43 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 225,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001055726-23-000006 · wf-form4_167762417016584.xml · derivative · entry 7 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2033-02-27 F5 · derivative.exercise_date: The vesting schedule for the 225,000 options is as follows: 56,250 shares vested on February 27, 2023; 56,250 shares will vest on February 26, 2024; 56,250 shares will vest on February 26, 2025; and 56,250 shares will vest on February 26, 2026. Read SEC document |
| February 26, 2023 Filed Feb 28, 2023 22:43 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 46,267 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-23-000006 · wf-form4_167762417016584.xml · derivative · entry 6 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,533 Underlying: Common Stock · 46,267 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2022, the reporting person was granted 138,800 restricted stock units, vesting as follows: 46,267 shares vested on February 26, 2023; 46,267 shares will vest on February 26, 2024; and 46,266 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2022, the reporting person was granted 138,800 restricted stock units, vesting as follows: 46,267 shares vested on February 26, 2023; 46,267 shares will vest on February 26, 2024; and 46,266 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2022, the reporting person was granted 138,800 restricted stock units, vesting as follows: 46,267 shares vested on February 26, 2023; 46,267 shares will vest on February 26, 2024; and 46,266 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2023 Filed Feb 28, 2023 22:43 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 22,544 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-23-000006 · wf-form4_167762417016584.xml · derivative · entry 5 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,544 Underlying: Common Stock · 22,544 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2021, the reporting person was granted 67,633 restricted stock units, vesting as follows: 22,545 shares vested on February 26, 2022; 22,544 shares vested on February 26, 2023; and 22,544 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2021, the reporting person was granted 67,633 restricted stock units, vesting as follows: 22,545 shares vested on February 26, 2022; 22,544 shares vested on February 26, 2023; and 22,544 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2021, the reporting person was granted 67,633 restricted stock units, vesting as follows: 22,545 shares vested on February 26, 2022; 22,544 shares vested on February 26, 2023; and 22,544 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2023 Filed Feb 28, 2023 22:43 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 18,868 | $1.28 | $24,151.04 |
DisclosureSEC source: 0001055726-23-000006 · wf-form4_167762417016584.xml · nonDerivative · entry 4 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,558 F4 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (3) herein. Read SEC document |
| February 26, 2023 Filed Feb 28, 2023 22:43 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 46,267 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-23-000006 · wf-form4_167762417016584.xml · nonDerivative · entry 3 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2022, the reporting person was granted 138,800 restricted stock units, vesting as follows: 46,267 shares vested on February 26, 2023; 46,267 shares will vest on February 26, 2024; and 46,266 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2023 Filed Feb 28, 2023 22:43 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 9,069 | $1.28 | $11,608.32 |
DisclosureSEC source: 0001055726-23-000006 · wf-form4_167762417016584.xml · nonDerivative · entry 2 Humeau Laurent · CIK 0001770390 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,159 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.